Regular Cannabis Users Require Higher Anesthesia Doses for Wisdom Teeth

Study Links Cannabis Use to Elevated Sedative Requirements

Patients who use cannabis daily or near-daily needed measurably higher doses of sedatives to achieve adequate anesthesia during third-molar extractions, the study found. Researchers documented the phenomenon across multiple anesthetic agents, including propofol and midazolam, commonly used in outpatient oral surgery. Heavier users required larger adjustments. The data suggest a dose-response relationship.

The mechanism remains under investigation. Researchers point to cannabinoid receptor cross-tolerance. THC and other phytocannabinoids interact with CB1 receptors in the central nervous system, pathways that also modulate GABAergic sedative response. Chronic activation of these receptors may downregulate sensitivity, forcing clinicians to escalate dosing to achieve the same sedative endpoint.

Clinical Implications for Oral Surgeons and Anesthesiologists

The findings compel oral surgeons to screen patients for cannabis use before scheduling procedures, a step many practices currently omit. Standard pre-operative questionnaires often focus on alcohol, tobacco, and prescription drugs but treat cannabis inconsistently. This study argues for explicit disclosure protocols and dosing adjustments based on reported consumption frequency.

Underdosing poses risks. Patient movement during surgery, incomplete amnesia, or awareness under sedation can occur. Overdosing carries its own hazards, particularly respiratory depression in patients with undiagnosed pulmonary conditions. The study authors recommend titration protocols that account for cannabis history, starting with conservative increases and monitoring vital signs closely.

Scope and Methodology of the Research

The study enrolled patients undergoing impacted third-molar extraction at a single oral surgery center over an 18-month period. Participants self-reported cannabis use via confidential intake forms, categorizing frequency as none, occasional (less than weekly), regular (weekly), or daily. Anesthesiologists recorded initial and total doses of all sedatives administered, along with time to adequate sedation and recovery metrics.

The cohort included 240 patients. Daily users (n=48) required an average propofol dose 22% higher than non-users to reach the same Ramsay Sedation Scale score. Regular users (n=71) showed a 14% increase. Occasional users? No statistically significant difference. The study controlled for age, body mass index, and concurrent medication use.

Chronic cannabinoid exposure appears to reset the baseline threshold for GABAergic sedation, requiring clinicians to recalibrate dosing strategies in a patient population that's both large and growing.

Broader Context: Cannabis and Anesthesia Interactions

This study joins a decade of research documenting altered anesthetic response in cannabis users across surgical settings. A 2019 study in Journal of the American Osteopathic Association found similar propofol-dose escalations in colonoscopy patients. A 2022 review in Anesthesia & Analgesia flagged the issue as an emerging patient-safety concern, particularly as adult-use legalization expands and self-reported consumption rises.

The interaction extends beyond sedatives. Some studies report increased opioid requirements for post-operative pain control in chronic cannabis users, though the evidence remains mixed. For background on the pharmacology and clinical implications, see the CannIntel topic hub on cannabis and anesthesia interactions.

Patient-Disclosure Barriers and Stigma

One obstacle to safe dosing is patient reluctance to disclose cannabis use, even in states with legal adult-use markets. Surveys indicate that 30-40% of regular users don't volunteer the information to medical providers, fearing judgment, legal concerns, or perceived irrelevance. The study authors urge practices to frame cannabis-use questions in neutral, clinical language and to emphasize that disclosure directly affects procedural safety.

Some oral surgery centers have begun integrating cannabis-use screening into digital intake forms, normalizing the question alongside alcohol and tobacco. Early reports suggest higher disclosure rates when the question's embedded in a broader substance-use module rather than isolated.

Next Steps for Research and Clinical Practice

The authors call for multi-center trials to validate the findings and establish evidence-based dosing guidelines stratified by consumption frequency and route of administration. Edibles, concentrates, and flower may produce different tolerance profiles. The study also didn't differentiate between THC-dominant and CBD-rich products, a variable that likely matters.

Professional societies including the American Society of Anesthesiologists have begun drafting interim guidance. Until formal protocols emerge, the study recommends that clinicians ask about cannabis use, document responses, and adjust sedative dosing upward in known users while monitoring closely for adverse events. The next signal: whether insurers and accrediting bodies will mandate cannabis screening as a standard of care.